{"prompt": "['4.1.1', 'Inclusion Criteria', '109', '4.1.2', 'Exclusion Criteria', '110', '4.2', 'Method of Treatment Assignment and Blinding', '111', '4.3', 'Study Treatment', '111', '4.3.1', 'Formulation, Packaging, and Handling', '111', '4.3.1.1', 'Emicizumab', '111', '4.3.2', 'Dosage, Administration, and Compliance', '111', '4.3.2.1', 'Emicizumab', '111', '4.3.3', 'Investigational Medicinal Product Accountability', '113', '4.3.4', 'Continued Access to Emicizumab', '114', '4.4', 'Concomitant Therapy', '114', '4.4.1', 'Permitted Therapy', '114', '4.4.2', 'Prohibited Therapy', '116', '4.5', 'Study Assessments', '116', '4.5.1', 'Informed Consent Forms and Screening Log', '116', '4.5.2', 'Medical History and Demographic Data', '116', '4.5.3', 'Physical Examinations', '117', '4.5.4', 'Vital Signs', '117', '4.5.5', 'Concomitant Medications', '117', '4.5.6', 'Laboratory, Biomarker, and Other Biological Samples', '117', '4.5.6.1', 'Hematology and Blood Chemistry', '118', '4.5.6.2', 'Pregnancy Tests', '118', '4.5.6.3', 'HIV and Hepatitis Serology', '119', '4.5.6.4', 'Anti-FVIII Antibodies', '119', '4.5.6.5', 'Anti-emicizumab Antibodies', '119', '4.5.6.6', 'Pharmacokinetics', '119', '4.5.6.7', 'Biomarkers', '119', '4.5.6.8', 'Extra Testing with Use of Bypass Agents', '120', '4.5.6.9', 'Sampling Procedures and Sample Storage, Shipment and', 'Destruction', '120', '4.5.7', 'Bleed Assessments', '121', '4.5.7.1', 'Definition of a Bleed', '121', '4.5.7.2', 'Definition of a Target Joint', '122', '4.5.7.3', 'Bleed Sites', '122', '4.5.7.4', 'Definitions of Bleed Types', '122', 'Emicizumab - F. Hoffmann-La Roche Ltd', '70 / Protocol MO39129, Version 3']['4.5.8', 'Surgical Events', '123', '4.5.9', 'Patient-Reported Outcomes', '123', '4.5.9.1', 'HRQoL Assessments', '123', '4.5.9.2', 'Health Status Assessments (EQ-5D-5L)', '124', '4.5.9.3', 'Treatment Preference Questionnaire', '124', '4.6', 'Patient, Treatment, Study and Site Discontinuation', '124', '4.6.1', 'Patient Discontinuation', '124', '4.6.2', 'Study Treatment Discontinuation', '125', '4.6.3', 'Study and Site Discontinuation', '125', '5. ASSESSMENT OF SAFETY', '125', '5.1', 'Safety Plan', '125', '5.1.1', 'Risks Associated with Emicizumab', '126', '5.1.1.1', 'Injection-Site Reactions', '126', '5.1.1.2', 'Hypercoagulation and Thromboembolic Events', '126', '5.1.1.3', 'Thrombotic Microangiopathy', '126', '5.1.1.4', 'Hypersensitivity', '127', '5.1.2', 'Management of Patients Who Experience Specific', 'Adverse Events', '128', '5.1.3', 'Interpretation of Coagulation Assays for Patients', 'Receiving Emicizumab', '130', '5.2', 'Safety Parameters and Definitions', '130', '5.2.1', 'Adverse Events', '131', '5.2.2', 'Serious Adverse Events (Immediately Reportable to the', 'Sponsor)', '131', '5.2.3', 'Adverse Events of Special Interest (Immediately', 'Reportable to the Sponsor)', '132', '5.3', 'Methods and Timing for Capturing and Assessing', 'Safety Parameters', '132', '5.3.1', 'Adverse Event Reporting Period', '132', '5.3.2', 'Eliciting Adverse Event Information', '133', '5.3.3', 'Assessment of Severity of Adverse Events', '133', '5.3.4', 'Assessment of Causality of Adverse Events', '133', '5.3.5', 'Procedures for Recording Adverse Events', '134', '5.3.5.1', 'Injection Reactions', '134', '5.3.5.2', 'Diagnosis versus Signs and Symptoms', '134', '5.3.5.3', 'Adverse Events That Are Secondary to Other Events', '135', 'Emicizumab - F. Hoffmann-La Roche Ltd', '71 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}